Vincent Rajkumar Vincent Rajkumar, Divison of Hematology, Mayo Clinic At a section of the hematology meeting talking about newly diagnosed multiple myeloma and the evolving treatments, Vincent Rajkuma
Vincent Rajkumar
Vincent Rajkumar, Divison of Hematology, Mayo ClinicAt a section of the hematology meeting talking about newly diagnosed multiple myeloma and the evolving treatments,Vincent Rajkumardiscussed new agents such as lenolidamide and thalidomide. The Audio Journal of Oncology asked him how he makes decisions about how to treat multiple myeloma.
Related Episodes
New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia
Audio Journal of Oncology SAN DIEGO—The first-line treatment of choice for older patients with chronic lymphocytic leukemia (CLL) should now be single agent ibrutinib according to conclu
Ibrutinib: New Frontline Standard for Chronic Lymphocytic Leukemia?
SAN DIEGO—Patients 70 years old and younger with previously untreated chronic lymphocytic leukemia (CLL) lived longer and had progression of their disease delayed when treated with ibrutinib (an irrev
Audio Journal of Oncology in Advance – March 15th, 2008
Volume 16 Number 6 (March 15th, 2008) reporting from: 4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris) American Society of Hematology Annual Meeting (December 8-11, 2007